Oxidative stress markers in blood in systemic sclerosis: A meta-analysis

References

• Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med. 2009;360:1989–2003.
   PubMed Web of Science ®Google Scholar
• Guillevin L, Hunsche E, Denton CP, Krieg T, Schwierin B, Rosenberg D, et al. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO registry. Clin Exp Rheumatol. 2013;31:71–80.
   PubMed Web of Science ®Google Scholar
• Mathai SC, Hummers LK, Champion HC, Wigley FM, Zaiman A, Hassoun PM, et al. Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum. 2009;60:569–77.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Matucci Cerinic M. The emerging problem of oxidative stress and the role of antioxidants in systemic sclerosis. Clin Exp Rheumatol. 2001;19:4–8.
   PubMed Web of Science ®Google Scholar
• Lundberg AC, Akesson A, Akesson B. Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis. 1992;51:1143–8.
   PubMed Web of Science ®Google Scholar
• Servettaz A, Goulvestre C, Kavian N, Nicco C, Guilpain P, Chereau C, et al. Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse. J Immunol. 2009;182:5855–64.
   PubMed Web of Science ®Google Scholar
• Tikly M, Channa K, Theodorou P, Gulumian M. Lipid peroxidation and trace elements in systemic sclerosis. Clin Rheumatol. 2006;25:320–4.
   PubMed Web of Science ®Google Scholar
• Volpe A, Biasi D, Caramaschi P, Mantovani W, Bambara LM, Canestrini S, et al. Levels of F2-isoprostanes in systemic sclerosis: correlation with clinical features. Rheumatology (Oxford). 2006;45:314–20.
   PubMed Web of Science ®Google Scholar
• Zhou CF, Yu JF, Zhang JX, Jiang T, Xu SH, Yu QY, et al. N-acetylcysteine attenuates subcutaneous administration of bleomycin-induced skin fibrosis and oxidative stress in a mouse model of scleroderma. Clin Exp Dermatol. 2013;38:403–9.
   PubMed Web of Science ®Google Scholar
• Kawashiri SY, Ueki Y, Terada K, Yamasaki S, Aoyagi K, Kawakami A. Improvement of plasma endothelin-1 and nitric oxide in patients with systemic sclerosis by bosentan therapy. Rheumatol Int. 2014;34:221–5.
   PubMed Web of Science ®Google Scholar
• Abou-Raya A, Abou-Raya S, Helmii M. Statins as immunomodulators in systemic sclerosis. Ann N Y Acad Sci. 2007;1110:670–80.
   PubMed Web of Science ®Google Scholar
• Riccieri V, Spadaro A, Fuksa L, Firuzi O, Saso L, Valesini G. Specific oxidative stress parameters differently correlate with nailfold capillaroscopy changes and organ involvement in systemic sclerosis. Clin Rheumatol. 2008;27:225–30.
   PubMed Web of Science ®Google Scholar
• Ogawa F, Shimizu K, Muroi E, Hara T, Sato S. Increasing levels of serum antioxidant status, total antioxidant power, in systemic sclerosis. Clin Rheumatol. 2011;30:921–5.
   PubMed Web of Science ®Google Scholar
• Bourji K, Meyer A, Chatelus E, Pincemail J, Pigatto E, Defraigne JO, et al. High reactive oxygen species in fibrotic and nonfibrotic skin of patients with diffuse cutaneous systemic sclerosis. Free Radic Biol Med. 2015;87:282–9.
   PubMed Web of Science ®Google Scholar
• Silva I, Teixeira A, Oliveira J, Almeida I, Almeida R, Vasconcelos C. Predictive value of vascular disease biomarkers for digital ulcers in systemic sclerosis patients. Clin Exp Rheumatol. 2015;33:S127–S30.
   PubMedGoogle Scholar
• Bozkurt M, Dağ Ş, Oktayoglu P, Em S, Yüksel H, Çağlayan M, et al. Serum prolidase enzyme activity and oxidative status in patients with scleroderma. Acta Medica Mediterranea. 2014;30:127–32.
   Web of Science ®Google Scholar
• Ciurzynski M, Bienias P, Irzyk K, Kostrubiec M, Bartoszewicz Z, Siwicka M, et al. Serum endothelin-1 and NT-proBNP, but not ADMA, endoglin and TIMP-1 levels, reflect impaired right ventricular function in patients with systemic sclerosis. Clin Rheumatol. 2014;33:83–9.
   PubMed Web of Science ®Google Scholar
• Motegi S, Toki S, Yamada K, Uchiyama A, Ishikawa O. Elevated plasma homocysteine level is possibly associated with skin sclerosis in a series of Japanese patients with systemic sclerosis. J Dermatol. 2014;41:986–91.
   PubMed Web of Science ®Google Scholar
• Savas E, Aksoy N, Pehlivan Y, Sayiner ZA, Ozturk ZA, Tabur S, et al. Evaluation of oxidant and antioxidant status and relation with prolidase in systemic sclerosis. Wien Klin Wochenschr. 2014;126:341–6.
   PubMed Web of Science ®Google Scholar
• Schiopu E, Au KM, McMahon MA, Kaplan MJ, Divekar A, Singh RR, et al. Prevalence of subclinical atherosclerosis is increased in systemic sclerosis and is associated with serum proteins: a cross-sectional, controlled study of carotid ultrasound. Rheumatology (Oxford). 2014;53:704–13.
   PubMed Web of Science ®Google Scholar
• Caimi G, Hopps E, Montana M, Carollo C, Calandrino V, Incalcaterra E, et al. Nitric oxide metabolites (nitrite and nitrate) in several clinical condition. Clin Hemorheol Microcirc. 2014;56:359–69.
   PubMed Web of Science ®Google Scholar
• Cruz-Dominguez MP, Montes-Cortes DH, Olivares-Corichi IM, Vera-Lastra O, Medina G, Jara LJ. Oxidative stress in Mexicans with diffuse cutaneous systemic sclerosis. Rheumatol Int. 2013;33:2261–7.
   PubMed Web of Science ®Google Scholar
• Fabrini R, Rosato E, Gigante A, Bocedi A, Cianci R, Barbano B, et al. Erythrocyte glutathione transferase: a non-antibody biomarker for systemic sclerosis, which correlates with severity and activity of the disease. Cell Death Dis. 2013;4:e736.
   PubMed Web of Science ®Google Scholar
• Nazarinia M, Shams M, Sarvestani EK, Shenavande S, Khademalhosseini M, Khademalhosseini Z. Serum homocystein level in patients with scleroderma. Iran Red Crescent Med J. 2013;15:29–31.
   PubMed Web of Science ®Google Scholar
• Turiel M, Gianturco L, Ricci C, Sarzi-Puttini P, Tomasoni L, Colonna Vde G, et al. Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. Arthritis Care Res (Hoboken). 2013;65:274–80.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Giannakoulas G, Papadopoulou K, Karvounis H, Dimitroula H, Koliakos G, et al. Early detection of cardiac involvement in systemic sclerosis assessed by tissue-Doppler echocardiography: relationship with neurohormonal activation and endothelial dysfunction. J Rheumatol. 2010;37:993–9.
   PubMed Web of Science ®Google Scholar
• Blaise S, Maas R, Trocme C, Kom GD, Roustit M, Carpentier PH, et al. Correlation of biomarkers of endothelium dysfunction and matrix remodeling in patients with systemic sclerosis. J Rheumatol. 2009;36:984–8.
   PubMed Web of Science ®Google Scholar
• Tiev KP, Le-Dong NN, Duong-Quy S, Hua-Huy T, Cabane J, Dinh-Xuan AT. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide. 2009;20:200–6.
   PubMed Web of Science ®Google Scholar
• Khurma V, Meyer C, Park GS, McMahon M, Lin J, Singh RR, et al. A pilot study of subclinical coronary atherosclerosis in systemic sclerosis: coronary artery calcification in cases and controls. Arthritis Rheum. 2008;59:591–7.
   PubMed Web of Science ®Google Scholar
• Mok MY, Fung PC, Ooi C, Tse HF, Wong Y, Lam YM, et al. Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis. Clin Rheumatol. 2008;27:315–22.
   PubMed Web of Science ®Google Scholar
• Sfrent-Cornateanu R, Mihai C, Stoian I, Lixandru D, Bara C, Moldoveanu E. Antioxidant defense capacity in scleroderma patients. Clin Chem Lab Med. 2008;46:836–41.
   PubMed Web of Science ®Google Scholar
• Wipff J, Avouac J, Borderie D, Zerkak D, Lemarechal H, Kahan A, et al. Disturbed angiogenesis in systemic sclerosis: high levels of soluble endoglin. Rheumatology (Oxford). 2008;47:972–5.
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Volpe A, Canestrini S, Bambara LM, Faccini G, Carletto A, et al. Correlation between homocysteine plasma levels and nailfold videocapillaroscopic patterns in systemic sclerosis. Clin Rheumatol. 2007;26:902–7.
   PubMed Web of Science ®Google Scholar
• Balbir-Gurman A, Braun-Moscovici Y, Livshitz V, Schapira D, Markovits D, Rozin A, et al. Antioxidant status after iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis. Clin Rheumatol. 2007;26:1517–21.
   PubMed Web of Science ®Google Scholar
• Dooley A, Gao B, Bradley N, Abraham DJ, Black CM, Jacobs M, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45:676–84.
   PubMed Web of Science ®Google Scholar
• Firuzi O, Fuksa L, Spadaro C, Bousova I, Riccieri V, Spadaro A, et al. Oxidative stress parameters in different systemic rheumatic diseases. J Pharm Pharmacol. 2006;58:951–7.
   PubMed Web of Science ®Google Scholar
• Kawaguchi Y, Tochimoto A, Hara M, Kawamoto M, Sugiura T, Katsumata Y, et al. NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity. Arthritis Res Ther. 2006;8:R104.
   PubMedGoogle Scholar
• Musellim B, Ikitimur H, Uzun H, Ongen G. The oxidant-antioxidant balance in systemic sclerosis cases with interstitial lung involvement. Rheumatol Int. 2006;27:163–7.
   PubMed Web of Science ®Google Scholar
• Peterlana D, Puccetti A, Caramaschi P, Biasi D, Beri R, Simeoni S, et al. Endothelin-1 serum levels correlate with MCP-1 but not with homocysteine plasma concentration in patients with systemic sclerosis. Scand J Rheumatol. 2006;35:133–7.
   PubMed Web of Science ®Google Scholar
• Fontana F, Bernardi P, Lanfranchi G, Conti E, Spampinato S, Di Toro R, et al. Endothelin-1 response to mental stress in early ischemic lesions of the extremities due to systemic sclerosis. Peptides. 2005;26:2487–90.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Acute and sustained effects of dihydropyridine-type calcium channel antagonists on oxidative stress in systemic sclerosis. Am J Med. 2004;116:595–600.
   PubMed Web of Science ®Google Scholar
• Caramaschi P, Martinelli N, Biasi D, Carletto A, Faccini G, Volpe A, et al. Homocysteine plasma concentration is related to severity of lung impairment in scleroderma. J Rheumatol. 2003;30:298–304.
   PubMed Web of Science ®Google Scholar
• Takagi K, Kawaguchi Y, Hara M, Sugiura T, Harigai M, Kamatani N. Serum nitric oxide (NO) levels in systemic sclerosis patients: correlation between NO levels and clinical features. Clin Exp Immunol. 2003;134:538–44.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Hilliquin P, Hernvann A, Levacher M, Lemarechal H, et al. Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology (Oxford). 2001;40:1089–96.
   PubMed Web of Science ®Google Scholar
• Andersen GN, Caidahl K, Kazzam E, Petersson AS, Waldenstrom A, Mincheva-Nilsson L, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum. 2000;43:1085–93.
   PubMed Web of Science ®Google Scholar
• Marasini B, Casari S, Bestetti A, Maioli C, Cugno M, Zeni S, et al. Homocysteine concentration in primary and systemic sclerosis associated Raynaud's phenomenon. J Rheumatol. 2000;27:2621–3.
   PubMed Web of Science ®Google Scholar
• Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K, et al. Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology (Oxford). 1999;38:309–15.
   PubMed Web of Science ®Google Scholar
• Levy Y, George J, Langevitz P, Harats D, Doolman R, Sela BA, et al. Elevated homocysteine levels in patients with Raynaud's syndrome. J Rheumatol. 1999;26:2383–5.
   PubMed Web of Science ®Google Scholar
• Olczyk K, Kucharz EJ, Winsz K, Bogdanowski T, Brzezińska-Wcisło L, Haj-Ali Y. Free radical activity and antioxidative systems in patients with systemic sclerosis. Eur J Intern Med. 1999;10:206–8.
   Google Scholar
• Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol. 1998;25:314–7.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM, et al. Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol. 1996;23:650–3.
   PubMed Web of Science ®Google Scholar
• Blann AD, Illingworth K, Jayson MI. Mechanisms of endothelial cell damage in systemic sclerosis and Raynaud's phenomenon. J Rheumatol. 1993;20:1325–30.
   PubMed Web of Science ®Google Scholar
• Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJ. Further evidence of increased polymorphonuclear cell activity in patients with Raynaud's phenomenon. Br J Rheumatol. 1992;31:375–80.
   PubMedGoogle Scholar
• Lau CS, O'Dowd A, Belch JJ. White blood cell activation in Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. Ann Rheum Dis. 1992;51:249–52.
   PubMed Web of Science ®Google Scholar
• Demitsu T, Katayama H, and Yaoita H. Serum lipid peroxide levels in various dermatoses. J Dermatol. 1988;15:325–9.
   PubMedGoogle Scholar
• Hassan I, Sajad P, Majid S, and Hassan T. Serum antioxidant status in patients with systemic sclerosis. Indian J Dermatol. 2013;58:239.
   PubMedGoogle Scholar
• Kalin R, Righi A, Rosso AD, Bagchi D, Generini S, Cerinic MM, et al. Activin, a grape seed-derived proanthocyanidin extract, reduces plasma levels of oxidative stress and adhesion molecules (ICAM-1, VCAM-1 and E-selectin) in systemic sclerosis. Free Radic Res. 2002;36:819–25.
   PubMed Web of Science ®Google Scholar
• Michel P, Eggert W, Albrecht-Nebe H, Grune T. Increased lipid peroxidation in children with autoimmune diseases. Acta Paediatr. 1997;86:609–12.
   PubMed Web of Science ®Google Scholar
• Dimitroulas T, Giannakoulas G, Sfetsios T, Karvounis H, Dimitroula H, Koliakos G, et al. Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension. Rheumatology (Oxford). 2008;47:1682–5.
   PubMed Web of Science ®Google Scholar
• Szamosi S, Csiki Z, Szomjak E, Szolnoki E, Szoke G, Szekanecz Z, et al. Plasma homocysteine levels, the prevalence of methylenetetrahydrofolate reductase gene C677T polymorphism and macrovascular disorders in systemic sclerosis: risk factors for accelerated macrovascular damage? Clin Rev Allergy Immunol. 2009;36:145–9.
   PubMed Web of Science ®Google Scholar
• Allanore Y, Borderie D, Lemarechal H, Ekindjian OG, Kahan A. Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1. Arthritis Res Ther. 2004;6:R309–14.
   PubMedGoogle Scholar
• Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MI. Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol. 1994;21:1477–83.
   PubMed Web of Science ®Google Scholar
• Clancy RM, Amin AR, Abramson SB. The role of nitric oxide in inflammation and immunity. Arthritis Rheum. 1998;41:1141–51.
   PubMed Web of Science ®Google Scholar
• Matucci Cerinic M, Kahaleh MB. Beauty and the beast. The nitric oxide paradox in systemic sclerosis. Rheumatology (Oxford). 2002;41:843–7.
   PubMed Web of Science ®Google Scholar
• Cracowski JL, Girolet S, Imbert B, Seinturier C, Stanke-Labesque F, Bessard J, et al. Effects of short-term treatment with vitamin E in systemic sclerosis: a double blind, randomized, controlled clinical trial of efficacy based on urinary isoprostane measurement. Free Radic Biol Med. 2005;38:98–103.
   PubMed Web of Science ®Google Scholar
• Correa MJ, Mariz HA, Andrade LE, Kayser C. [Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial]. Rev Bras Reumatol. 2014;54:452–8.
   PubMed Web of Science ®Google Scholar